期刊文献+

非肥胖多囊卵巢综合征患者网膜脂肪PPARγ_2 mRNA表达及与IR的关系

Expression of peroxisome proliferator-activated receptor gamma 2 in omental adipose tissue of nonobese polycystic ovary syndrome subjects and its relationship with insulin resistance
下载PDF
导出
摘要 目的探讨过氧化物酶体增殖物激活受体γ2(PPARγ2)基因在非肥胖多囊卵巢综合征(PCOS)患者网膜脂肪组织的表达水平与胰岛素抵抗(IR)的相关性。方法选取非肥胖PCOS患者(观察组)11例和非PCOS患者18例(对照组),采用RT-PCR法检测两组网膜脂肪组织PPARγ2mRNA表达水平,测定空腹血糖、空腹胰岛素(FINS),计算稳态模型胰岛素抵抗指数(HOMA-IR)。结果观察组HOMA-IR明显高于对照组,P<0.01;余指标比较无统计学差异。相关性分析示,PPARγ2 mRNA表达水平与FINS、HOMA-IR等均无相关性。结论非肥胖P-COS患者网膜脂肪组织PPARγ2 mRNA的表达水平与IR无明显相关性。 Objective To investigate the expression of peroxisome proliferator-activated receptor γ2 ( PPARγ2 ) in omental adipose tissue of nonobese polycystic ovary syndrome (PCOS) subjects and its relationship with insulin resistance (IR). Methods Eleven nonobese PCOS subjects (observation group)and eighteen non-PCOS patients (control group) were chosen to detect the PPAR3'2 mRNA expression level of omental adipose tissue by RT-PCR, fasting plasma glucose (FPG) and fasting plasma insulin (FINS) were measured to calculate homeostasis model insulin resistance index( HOMAIR). Results The level of HOMA-IR in observation group were higher than that in control group (P 〈 0.01 ) ; while the other parameters had no statistically significant difference. The correlation analysis showed that the expression level of PPARγ2 mRNA had no correlation with FINS and HOMA-IR. Conclusions The expression level of omental adipose tissue PPARγ2 mRNA had no correlation with insulin resistance in nonobese PCOS subjects.
作者 李艳 谭丽
出处 《山东医药》 CAS 2012年第19期43-45,共3页 Shandong Medical Journal
基金 河南省省级医学高新技术发展扶持项目(200803060)
关键词 多囊卵巢综合征 脂肪组织 过氧化物酶体增殖物激活受体γ2 胰岛素抵抗 polycystic ovary syndrome adipose tissue peroxisome proliferator-activated receptor γ2 insulin resistance
  • 相关文献

参考文献10

  • 1李美芝,李蓉.多囊卵巢综合征诊断的金标准:鹿特丹标准?[J].中国实用妇科与产科杂志,2007,23(9):657-659. 被引量:155
  • 2Ovalle F, Azziz R. Insulin resistance, polyeystie ovary syndrome, and type 2 diabetes mellitus [ J ]. Fertil Steril, 2002,77 (6) :1095- 1105.
  • 3Sewter C, Blows F, Considine R, et al. Differential effects of adi- posity on perxisomal proliferator-activated receptor gammal and gam- ma2 messenger ribonucleic acid expression in human adipocytes[ J ]. J. Clin Endoc and Metab, 2002,87(9) :4203-4207.
  • 4Vidal-PuigA J, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glu- cocorticoids[ J]. J Clin Invest, 1997,99(10) :2416-2422.
  • 5Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein : Evidence for a peripheral signal linking adiposity and centralneural networks s[ J]. Science, 1995,269 (5223) :546-549.
  • 6Mukherjee R, Hoener PA, Jow L, et al. A selective peroxisome proliferator-activated receptors(PPAR',/) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes [J]. Mol Endocrinol, 2000,14(9) :1425-1433.
  • 7Giusti V, Verdumo C, Suter M, et al. Expression of peroxisome proliferator-activated receptor PPAR3,1 and pemxisome proliferator- activated receptor PPAR2 in visceral and subcutaneous adipose tis- sue of obese women[ J]. Diabetes, 2003,52(7) :1673-1676.
  • 8Hara M, Alcoser SY, Qaadir A, et al. Insulin resistance is attenua- ted in women with polycystic ovary syndrome with the Pro(12) Ala polymorphism in the PPAR/ Gene [ J ]. J Clin Endocrinol Metab, 2002,87(2) :772-775.
  • 9Tai ES, Corella D, Deurenberg-Yap M, et al. Differential effects of the C1431T and Prol2Ala PPAR gene variants on plasma lipids and diabetes risk in an Asian population [ J ]. J Lipid Res, 2004,45 (4) :674-685.
  • 10Floyd ZE, Stephens JM. Control of peroxisome proliferator-activa- ted receptor gamma2 stability and activity by SUMOylation [ J ]. Obes Res, 2004,12(6):921-928.

二级参考文献13

  • 1Azziz R,Woods KS,Reyna R,et al.The prevalence and features of the polycystic ovary syndrome in an unselected population[J].J Clin Endocrinol Metab,2004,89:2745-2749.
  • 2Adams J,Polson DW,Franks S.Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsute[J].Br Med J,1986,293:355-359.
  • 3Polson DW,Adams J,Wadsworth J,et al.Polycystic ovaries a common finding in normal women[J].Lancet,1988,16:870-872.
  • 4Clayton RN,Ogden V,Hodgkinson J,et al.How common are polycystic ovaries in normal women and what is the insignificance for the infectility of the population?[J].Clin Endocrinol,1972,37:127-134.
  • 5Farguan CM,Bindsall M,Manning P,et al.The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women[J].Aust N Z J Obstet Gynecol,1994,34:67-72.
  • 6Michelmone KF,Balen AH,Dungen DB,et al.Polycystic ovaries and associated clinical and biochemical features in young women[J].Clin Endocrinol,1999,51:779-786.
  • 7Koivunen R,Lantikainen T,Tomas C,et al.The prevalence of polycystic ovaries in healthy women[J].Acta Obstet Gynecol Scanal,1999,78:137-141.
  • 8Fox R.Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomennorrhea[J].Aust N Z J Obstet Gynecol,1999,39:63-68.
  • 9Carmina E,Lobo RA.Do hyperandrogenic women with normal menses have polycystic ovary syndrome?[J].Fertil Steril,1997,71:319-322.
  • 10Solomon CG.The epidemiology of polycystic ovary syndrome:prevenlance and associated disease risk[J].Endocrinol Metab Clin North Am,1999,28:247-264.

共引文献154

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部